MAPT and Alzheimer disease: One emerging approach is the targeted degradation of specific molecules by proteolysis targeting chimeric molecules (PROTACs).107 Theoretically, PROTACs could be developed for the degradation of proteases involved in Aβ42 production or misfolded tau.91 However, the impact of Aβ and tau on the efficacy of PROTACs in AD needs to be overcome for this approach to be effective.